Combined Empagliflozin and Sacubitril/Valsartan Therapy Additively Improves Cardiorenal Function Through AMPK Activation and Angiotensin II Type 1 Receptor Signaling Attenuation in a Rat Model of Cardiorenal Syndrome
The FASEB Journal · 31.03.2026 · 40 (6)
DOI: 10.1096/fj.202503723r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 19.03.2026. Verfasst von Yi-Chen Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medicine Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Valsartan, Glucosides, Aminobutyrates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital (CGMH), Ministry of Health and Welfare (MOHW), National Cheng Kung University Hospital (NCKU).
Abstract (Originalsprache)
Cardiorenal syndrome (CRS) is characterized by a bidirectional impairment of cardiac and renal function, associated with high mortality and limited effective therapeutic options. This study evaluated the cardiorenal protective effects of combined sodium–glucose cotransporter‐2 inhibition (empagliflozin) and angiotensin receptor–neprilysin inhibition (sacubitril/valsartan) in an experimental model of CRS. Adult Sprague–Dawley rats were subjected to 5/6 nephrectomy and doxorubicin administration, followed by a high‐protein diet to induce CRS. Animals were randomized to receive empagliflozin, sacubitril/valsartan, a combination of both agents, and no treatment for 60 days. Endpoints included survival, assessment of cardiorenal function, circulating biomarkers, histopathological analysis, and evaluation of signaling pathways implicated in fibrosis, oxidative stress, and inflammation. Combination therapy resulted in a 60‐day survival rate of 89%, compared to 50% in untreated controls and 75%–78% with either monotherapy. All active treatments significantly preserved both cardiac and renal function, reduced levels of oxidized low‐density lipoproteins, and attenuated interstitial fibrosis by inhibiting the TGF‐β/Smad3 pathway. Furthermore, these therapies activated the AMPK–PGC‐1α–SIRT1 signaling axis and suppressed angiotensin II/AT1 receptor signaling, resulting in decreased reactive oxygen species and inflammatory mediators, including NOX2, NOX4, IL‐6, IL‐1β, TNF‐α, and phosphorylated NF‐κB. Across all evaluated parameters, combination therapy consistently demonstrated the most pronounced protective effects. Collectively, these findings provide compelling preclinical evidence that concomitant administration of empagliflozin and sacubitril/valsartan confers superior cardiorenal protection and enhances survival in a rodent CRS model, supporting further clinical investigation of this combinatory therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Medicine Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Center of Cell Therapy, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Department of Radiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- University Center for Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan.
ORCID-Profile: Yi-Chen Li, Chih-Chao Yang
Förderung
- Chang Gung Memorial Hospital (CGMH)
- Ministry of Health and Welfare (MOHW)
- National Cheng Kung University Hospital (NCKU)
- National Science and Technology Council (NSTC)
Zitieren
APA
Li, Y. C., Chai, H. T., Ko, S. F., Chang, C. K., Chu, C. H., Cheng, B. C., Yip, H. K., & Yang, C. C. (2026). Combined Empagliflozin and Sacubitril/Valsartan Therapy Additively Improves Cardiorenal Function Through AMPK Activation and Angiotensin II Type 1 Receptor Signaling Attenuation in a Rat Model of Cardiorenal Syndrome. The FASEB Journal, 40(6). https://doi.org/10.1096/fj.202503723r
Vancouver
Li YC, Chai HT, Ko SF, Chang CK, Chu CH, Cheng BC, et al. Combined Empagliflozin and Sacubitril/Valsartan Therapy Additively Improves Cardiorenal Function Through AMPK Activation and Angiotensin II Type 1 Receptor Signaling Attenuation in a Rat Model of Cardiorenal Syndrome. The FASEB Journal. 2026;40(6). doi:10.1096/fj.202503723r
BibTeX
@article{Li2026,
author = {Li, Yi-Chen and Chai, Han-Tan and Ko, Sheung-Fat and Chang, Ching-Kun and Chu, Chi-Hsiang and Cheng, Ben-Chung and Yip, Hon-Kan and Yang, Chih-Chao},
title = {Combined Empagliflozin and Sacubitril/Valsartan Therapy Additively Improves Cardiorenal Function Through AMPK Activation and Angiotensin II Type 1 Receptor Signaling Attenuation in a Rat Model of Cardiorenal Syndrome},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {6},
doi = {10.1096/fj.202503723r}
}
EUVIMED